ERBB2 and breast cancer: As noted above, PAQR8 CN gain in recurrent breast cancers was not restricted to hormone receptor-positive tumors and occurred with equal frequency in recurrent metastatic tumors in patients treated with other forms of therapy, including chemotherapy and anti-Her2 therapy [3].